Thermo Fisher Scientific Inc. (TMO) Stock Score, Valuation & Financial Research
Thermo Fisher Scientific Inc. is in the Healthcare sector and Medical - Diagnostics & Research industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 34/100.
Quick answer for TMO
Thermo Fisher Scientific Inc. currently has a Wall Street Score of 34/100. The stored market price is $609.82. Its financial score is 28/100. Its valuation score is 10/100. These figures are a research snapshot, not a buy or sell recommendation.
What Thermo Fisher Scientific Inc. does
Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services. The company's reach extends across North America, Europe, Asia-Pacific, and other international markets. Its Life Sciences Solutions division furnishes researchers with essential reagents, state-of-the-art instruments, and consumables vital for biological and medical exploration, the development and manufacturing of therapeutics and vaccines, and the detection of infections and various diseases. This segment encompasses bioscience, genetic science, and bioproduction technologies, serving a broad spectrum of clients in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, a
TMO financial snapshot
- Wall Street Score:
- 34/100
- Current price:
- $609.82
- Market capitalization:
- $226.62B
- Revenue:
- $46.34B
- Net income:
- $6.98B
- Free cash flow:
- $6.29B
- Cash:
- $4.06B
- Total debt:
- $42.55B
- EPS:
- 17.77
- P/E ratio:
- 34.3x
- Financial score:
- 28/100
- Valuation score:
- 10/100
- Revenue score:
- 17/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $6.29B, showing positive cash generation.
- The balance sheet shows $4.06B of cash versus $42.55B of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 10/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 28/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research TMO
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.